Company CARsgen Therapeutics Holdings Limited

Equities

2171

KYG1996C1006

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Hong Kong S.E. Other stock markets 04:08:03 2024-05-23 am EDT			5-day change	1st Jan Change
6.65 ^HKD	+3.42%		+7.95%	+2.31%

Apr. 30	CARsgen Therapeutics Holdings Limited Announces Abstracts from the Ongoing Studies of zevorcabtagene autoleucel and CT071 to be Presented as an Oral Presentation and a Poster Presentation, Respectively, at the Upcoming EHA 2024	CI
Apr. 29	CARsgen Therapeutics Holdings Limited Announces Board and Committee Changes	CI

CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Companyâs therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.

Number of employees: 516

Managers	Title	Age	Since
Hua Mao Wang FOU	Founder	48	18-02-08
Zong Hai Li CEO	Chief Executive Officer	51	18-02-08
Lan Xie DFI	Director of Finance/CFO	52	21-02-28
Hong Ma CTO	Chief Tech/Sci/R&D Officer	54	18-07-31
Raffaele Baffa CTO	Chief Tech/Sci/R&D Officer	65	22-04-06
Hua Jiang BRD	Director/Board Member	45	21-03-31
Sylvie Peltier LAW	General Counsel	60	22-10-30
Guan Jun Zhou LAW	General Counsel	-	-
Wing Yat Lui SEC	Corporate Secretary	35	21-02-22
Leigh Hsu PRN	Corporate Officer/Principal	54	17-05-31

Members of the board	Title	Age	Since
Zong Hai Li CEO	Chief Executive Officer	51	18-02-08
Hua Mao Wang FOU	Founder	48	18-02-08
Xiang Ke Zhao BRD	Director/Board Member	38	23-07-03
Rong Gang Xie BRD	Director/Board Member	39	20-09-17
Bing Sen Guo BRD	Director/Board Member	54	18-09-12
Hua Qing Guo BRD	Director/Board Member	36	20-09-17
Guang Mei Yan BRD	Director/Board Member	67	21-06-17
Hua Jiang BRD	Director/Board Member	45	21-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	575,643,915	337,141,699 ( 58.57 %)	0	58.57 %

Name	Equities	%	Valuation
Zong Hai Li 37.59 %	216,387,730	37.59 %	164 M $
Aegon-Industrial Fund Management Co., Ltd. 4.201 %	24,183,000	4.201 %	18 M $
Loyal Valley Capital Co. Ltd. 3.860 %	22,222,244	3.860 %	17 M $
Fullgoal Fund Management Co., Ltd. 1.121 %	6,454,000	1.121 %	5 M $
Shanghai Bioveda Investment Management Consulting Co. Ltd. 1.098 %	6,317,706	1.098 %	5 M $
HSBC Jintrust Fund Management Co. Ltd. 0.8222 %	4,733,000	0.8222 %	4 M $
Hua Jiang 0.5005 %	2,880,992	0.5005 %	2 M $
GF Fund Management Co., Ltd. 0.4795 %	2,760,500	0.4795 %	2 M $
Bosera Asset Management Co., Ltd. 0.4637 %	2,669,500	0.4637 %	2 M $
Fullgoal Asset Management (HK) Ltd. 0.3311 %	1,906,000	0.3311 %	1 M $

CARsgen Therapeutics Holdings Ltd.

CMC Preparation Center No. 388 Yindu Road

200231, Shanghai

http://www.carsgen.com

address CARsgen Therapeutics Holdings Limited(2171)

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6.167 CNY

Average target price

6.662 CNY

Spread / Average Target

+8.02%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CARSGEN THERAPEUTICS HOLDINGS LIMITED	+2.31%	474M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs